SMT202000059T1 - Composti e composizioni per modulare attività chinasiche di egfr mutante - Google Patents

Composti e composizioni per modulare attività chinasiche di egfr mutante

Info

Publication number
SMT202000059T1
SMT202000059T1 SM20200059T SMT202000059T SMT202000059T1 SM T202000059 T1 SMT202000059 T1 SM T202000059T1 SM 20200059 T SM20200059 T SM 20200059T SM T202000059 T SMT202000059 T SM T202000059T SM T202000059 T1 SMT202000059 T1 SM T202000059T1
Authority
SM
San Marino
Prior art keywords
compositions
compounds
kinase activities
egfr mutant
mutant kinase
Prior art date
Application number
SM20200059T
Other languages
English (en)
Italian (it)
Inventor
Byung-Chul Suh
Paresh Devidas Salgaonkar
Jaekyoo Lee
Jong Sung Koh
Ho-Juhn Song
In Yong Lee
Jaesang Lee
Dong Sik Jung
Jung-Ho Kim
Se-Won Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000059(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of SMT202000059T1 publication Critical patent/SMT202000059T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
SM20200059T 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante SMT202000059T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
EP15850314.4A EP3207035B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number Publication Date
SMT202000059T1 true SMT202000059T1 (it) 2020-03-13

Family

ID=55654993

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20200059T SMT202000059T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante
SM20210266T SMT202100266T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante.
SM20250069T SMT202500069T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare le attività della chinasi mutante egfr

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20210266T SMT202100266T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante.
SM20250069T SMT202500069T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare le attività della chinasi mutante egfr

Country Status (30)

Country Link
US (2) US9593098B2 (enExample)
EP (4) EP3604294B1 (enExample)
JP (3) JP6524221B2 (enExample)
KR (5) KR102208775B1 (enExample)
CN (2) CN106795144B (enExample)
AU (1) AU2015331166B2 (enExample)
BR (1) BR112017007769B1 (enExample)
CA (1) CA2962914C (enExample)
CY (2) CY1122737T1 (enExample)
DK (3) DK3604294T3 (enExample)
ES (3) ES2770058T3 (enExample)
FI (2) FI3929190T3 (enExample)
FR (1) FR25C1021I1 (enExample)
HR (3) HRP20200201T1 (enExample)
HU (4) HUE054848T2 (enExample)
LT (4) LT3207035T (enExample)
MX (3) MX2017003181A (enExample)
NL (1) NL301329I2 (enExample)
NO (1) NO2025025I1 (enExample)
NZ (1) NZ730012A (enExample)
PH (1) PH12017500488A1 (enExample)
PL (3) PL3604294T3 (enExample)
PT (3) PT3207035T (enExample)
RS (3) RS66529B1 (enExample)
RU (1) RU2727700C2 (enExample)
SG (1) SG11201701960XA (enExample)
SI (3) SI3207035T1 (enExample)
SM (3) SMT202000059T1 (enExample)
TW (2) TWI730331B (enExample)
WO (1) WO2016060443A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730331B (zh) 2014-10-13 2021-06-11 南韓商柳韓洋行股份有限公司 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
KR20180105161A (ko) 2016-01-07 2018-09-27 씨에스 파마테크 리미티드 Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
SG11201809751XA (en) * 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR102388312B1 (ko) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 아미노피리미딘 화합물, 이의 제조방법 및 용도
MY198379A (en) * 2017-07-28 2023-08-28 Yuhan Corp Improved Process for Preparing Aminopyrimidine Derivatives
MA49703A (fr) * 2017-07-28 2021-04-21 Yuhan Corp Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
JP7189932B2 (ja) * 2017-07-28 2022-12-14 ユハン コーポレーション タンパク質キナーゼに対する選択的阻害剤の合成に有用な中間体及びそれを調製するためのプロセス
EP3653622B1 (en) * 2017-08-30 2022-12-28 Shenzhen TargetRx, Inc. Aminopyrimidine compound and composition comprising same and use thereof
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US12312329B2 (en) * 2018-12-21 2025-05-27 Shenzhen Targetrx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
US11459391B2 (en) 2019-02-26 2022-10-04 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
CA3134261A1 (en) * 2019-03-19 2020-09-24 Voronoi Inc. 6-(isooxazolidin-2-yl)-n-phenylpyrimidin-4-amine derivatives as inhibitors of epidermal growth factor receptors
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
MX2021011810A (es) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
CN111747931A (zh) 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
CA3191538A1 (en) 2020-09-14 2022-03-17 Ademi Elena SANTIAGO-WALKER Fgfr inhibitor combination therapies
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
JP2024516721A (ja) * 2021-05-07 2024-04-16 ボロノイ インコーポレイテッド ヘテロアリール誘導体、これを製造する方法、およびこれを有効成分として含む薬学的組成物
AU2022271388A1 (en) 2021-05-17 2022-12-01 Voronoi Inc. Heteroaryl derivative compounds, and uses thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
KR20250097933A (ko) * 2022-11-03 2025-06-30 보로노이 주식회사 Egfr 억제제의 퓨마르산염, 타타르산염, 말산염, 및 시트르산염
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech Inc Methods for treatment of non-small cell lung cancer (nsclc)
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172005B1 (en) 1997-03-11 2001-01-09 E. I. Du Pont De Nemours And Company Heteroaryl azole herbicides
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
GB2450046B (en) 2006-03-29 2011-03-09 Kt Freetel Co Ltd Digital device and method for providing additional service by using the same
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
AU2007238897A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
WO2011060295A1 (en) * 2009-11-13 2011-05-19 Genosco Kinase inhibitors
US9890138B2 (en) 2011-02-25 2018-02-13 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
PT3009431T (pt) * 2011-07-27 2017-12-26 Astrazeneca Ab Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro
KR101944914B1 (ko) * 2012-01-20 2019-02-07 제노스코 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US10273224B2 (en) * 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN111892579B (zh) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
EP3157916B1 (en) 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
TWI730331B (zh) * 2014-10-13 2021-06-11 南韓商柳韓洋行股份有限公司 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
KR20240074820A (ko) 2024-05-28
KR20210011068A (ko) 2021-01-29
SMT202100266T1 (it) 2021-07-12
MX2017003181A (es) 2017-07-20
DK3207035T3 (da) 2020-01-27
KR20230010836A (ko) 2023-01-19
PL3207035T3 (pl) 2020-06-01
EP3207035A2 (en) 2017-08-23
JP6754864B2 (ja) 2020-09-16
EP3207035A4 (en) 2018-03-14
EP3929190B1 (en) 2024-12-25
RU2020123547A (ru) 2020-08-18
EP3604294B1 (en) 2021-05-05
JP6524221B2 (ja) 2019-06-05
CA2962914A1 (en) 2016-04-21
LT3207035T (lt) 2020-02-25
KR20170066650A (ko) 2017-06-14
EP4421069B1 (en) 2025-12-10
NL301329I2 (nl) 2025-09-09
LTPA2025522I1 (enExample) 2025-06-25
PH12017500488A1 (en) 2017-07-31
CN106795144A (zh) 2017-05-31
BR112017007769A2 (pt) 2018-01-16
TW201619150A (zh) 2016-06-01
RU2017116598A3 (enExample) 2018-11-21
TWI730331B (zh) 2021-06-11
US9593098B2 (en) 2017-03-14
SI3604294T1 (sl) 2021-08-31
AU2015331166B2 (en) 2018-04-26
RU2727700C2 (ru) 2020-07-23
PT3207035T (pt) 2020-02-19
KR102662358B1 (ko) 2024-04-30
USRE50528E1 (en) 2025-08-12
MX2021010761A (es) 2022-06-09
TW201938553A (zh) 2019-10-01
PL3929190T3 (pl) 2025-06-09
EP3207035B1 (en) 2019-11-20
HRP20250213T1 (hr) 2025-04-25
KR102073854B1 (ko) 2020-02-05
PT3604294T (pt) 2021-07-29
SI3929190T1 (sl) 2025-04-30
KR102208775B1 (ko) 2021-01-28
EP4421069A1 (en) 2024-08-28
RU2017116598A (ru) 2018-11-21
US20160102076A1 (en) 2016-04-14
EP3604294A1 (en) 2020-02-05
KR102487451B1 (ko) 2023-01-11
RS66529B1 (sr) 2025-03-31
NO2025025I1 (no) 2025-06-05
DK3929190T3 (da) 2025-02-24
HUE070874T2 (hu) 2025-07-28
SMT202500069T1 (it) 2025-03-12
PT3929190T (pt) 2025-02-19
CN106795144B (zh) 2020-06-16
CY1122737T1 (el) 2021-03-12
LT3929190T (lt) 2025-02-25
FI3929190T3 (fi) 2025-02-28
KR20200014944A (ko) 2020-02-11
TWI664173B (zh) 2019-07-01
HUE048006T2 (hu) 2020-05-28
JP2019163277A (ja) 2019-09-26
NZ730012A (en) 2019-06-28
HUS2500023I1 (hu) 2025-06-28
ES2770058T3 (es) 2020-06-30
HRP20210949T1 (hr) 2021-09-03
LT3604294T (lt) 2021-07-26
FR25C1021I1 (fr) 2025-08-01
WO2016060443A3 (en) 2016-06-23
HUE054848T2 (hu) 2021-09-28
PL3604294T3 (pl) 2021-11-02
RS61865B1 (sr) 2021-06-30
FIC20250023I1 (fi) 2025-06-06
RS59900B1 (sr) 2020-03-31
CN111686110A (zh) 2020-09-22
SG11201701960XA (en) 2017-04-27
JP2017530999A (ja) 2017-10-19
HRP20200201T1 (hr) 2020-05-15
DK3604294T3 (da) 2021-06-28
CN111686110B (zh) 2023-06-16
WO2016060443A2 (en) 2016-04-21
MX385942B (es) 2025-03-18
CA2962914C (en) 2018-10-23
BR112017007769B1 (pt) 2023-10-10
AU2015331166A1 (en) 2017-03-30
ES3009926T3 (en) 2025-03-31
ES2879474T3 (es) 2021-11-22
CY1124359T1 (el) 2022-07-22
SI3207035T1 (sl) 2020-04-30
EP3929190A1 (en) 2021-12-29
MX2020002168A (es) 2021-09-07
JP2020196740A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
HUS2500023I1 (hu) Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL273058A (en) Compositions and methods for modulation of PKK expression
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
SG11201802798WA (en) Compounds, compositions, and methods for modulating cftr
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
IL246879A0 (en) Preparations of Epilimod and methods of using them
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
HUE037848T2 (hu) Vegyes gyep
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
SG10202003691PA (en) Composition for modulating irak1
GB201614961D0 (en) Compounds and compositions for use
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors